Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Raj R, Kaprio J, Jousilahti P et al (2022) Risk of dementia after hospitalization due to traumatic brain injury: a longitudinal, population-based study. Neurology. https://doi.org/10.1212/WNL.0000000000200290
2. Izzy S, Chen PM, Tahir Z et al (2022) Association of traumatic brain injury with the risk of developing chronic cardiovascular, endocrine, neurological, and psychiatric disorders. JAMA Netw Open 5(4):e229478–1
3. Pressemeldung des Herstellers: September 27, 2022: Lecanemab Confirmatory Phase 3 CLARITY AD Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction Of Clinical Decline In Large Global Clinical Study Of 1,795 Participants With Early Alzheimer's Disease.
4. Haeberlein SB, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early alzheimer's disease. J Prev Alzheimers Dis 9(2):197–210
5. Mintzer J, Lanctôt KL, Scherer RW et al (2021) Effect of methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol 78(11):1324–1332